If you’re having a heart failure crisis, every hour matters. Your cardiologist knows this. The research knows this. The clinical guidelines know this.
Your insurance company apparently does not.
A study published in March 2026 found that heart failure patients whose prescriptions required prior authorization took 3 times longer to fill ARNI prescriptions and 6 times longer to fill SGLT2 inhibitors compared to patients who didn’t need prior auth.
These aren’t experimental drugs
ARNIs (like sacubitril/valsartan) and SGLT2 inhibitors (like empagliflozin and dapagliflozin) are not new, unproven therapies. They are frontline, guideline-recommended treatments for heart failure. The evidence supporting them is overwhelming and has been for years:
- ARNIs reduce heart failure hospitalization by 21% and cardiovascular death by 20% compared to older ACE inhibitors (PARADIGM-HF trial)
- SGLT2 inhibitors reduce heart failure hospitalization by 25-30% regardless of diabetes status (DAPA-HF, EMPEROR-Reduced trials)
- Both are recommended as first-line therapy by the ACC/AHA heart failure guidelines
These are medications that cardiologists prescribe because the clinical evidence says they save lives. And yet a patient whose doctor prescribes one is waiting three to six times longer to actually get it, because someone at an insurance company needs to check a box first.
What 6x longer looks like in real life
Abstract numbers obscure real suffering. Here’s what a 6x delay looks like for a heart failure patient:
- Rationing old medication because the new prescription hasn’t been approved yet
- A midnight ER visit that didn’t need to happen, because symptoms escalated during the wait
- A family member calling the pharmacy again, being told “we’re still waiting to hear back”
- A hospital readmission that costs the system ten times what the medication would have cost
- Worsening cardiac function that may never fully recover, because early intervention matters in heart failure
Each of these scenarios is preventable. Not with better medicine — the medicine already exists. With better process.
The cost paradox
Here’s the cruel irony that should keep every health plan executive up at night: the prior authorization process that’s supposed to control costs is generating the exact hospitalizations and complications that drive costs through the roof.
A 30-day supply of an SGLT2 inhibitor costs roughly $500-600 at list price (less with negotiated rates). A single heart failure hospitalization costs $10,000-$15,000 on average. The math isn’t complicated.
Every day of delay increases the probability of decompensation. Every decompensation increases the probability of hospitalization. Every hospitalization costs orders of magnitude more than the medication that could have prevented it.
Prior authorization for guideline-recommended heart failure therapies doesn’t save money. It shifts costs from pharmacy budgets to hospital budgets — and shifts suffering onto patients.
The path forward
The prior authorization process for well-established, guideline-recommended therapies needs to be fundamentally rethought. For medications where the clinical evidence is unambiguous and the guidelines are clear, the authorization should be near-automatic.
At Artificer Health, we’re building a platform that understands payer-specific criteria and matches clinical documentation to requirements in real time. For cases like guideline-recommended heart failure medications, the system should recognize that the clinical evidence is settled and expedite authorization accordingly.
A cardiologist’s prescription shouldn’t need to survive a bureaucratic obstacle course before it reaches the patient. We’re building the technology to make sure it doesn’t have to.